Diabetomics Inc. Changes Name to Modality Dx Amid New Innovation and Expansion of Molecular Signature Diagnosis Products

Diabetomics has been rebranded Modality Dx. Founded by Dr. Srinivasa Nagalla, Modality Dx is an innovator in rapid test technologies for risk assessment and diagnosis in maternal health, diabetes and autoimmune disease.

“Throughout my career, I’ve seen firsthand the great need for more preventive healthcare solutions,” said Dr. Nagalla. “Too often doctors see patients after disease has already taken hold. My goal is to develop diagnostic tools that can assist in prevention and early intervention.”

Modality Dx has developed products that can identify molecular Signatures, provide rapid diagnostic testing, smart device technology and oral fluid technology.

Robert Gootee, Board Chair of Modality Dx, said, “The goal of our research is to develop products that help healthcare professionals identify and treat disease early and accurately, thus enabling them to focus on effective disease prevention.”

Currently, Modality Dx holds patents for rapid test products that enable disease diagnosis in maternal health, diabetes and rheumatoid arthritis. These patented science and technology products enhance the measurement of treatment efficacy, thus improving the pharmaceutical industry’s ability to identify precision targets that support drug development.

About Modality Dx

Modality Dx, a privately-held Oregon-based company founded in 2010, is focused on the rapid diagnosis of disease in the maternal health, diabetes and autoimmune sectors. Through science and business excellence, they are pioneering a quantitative precision-based approach to diseases diagnosis and treatment.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250618538946/en/